Alopecia Areata | Childhood Alopecia Areata Study Using the 308-nm Excimer Laser
Alopecia Areata research study
What is the primary objective of this study?
Alopecia Areata (AA) is a skin restricted autoimmune disease of the hair follicle, resulting in hair loss of the scalp, and in severe cases of the entire body. AA is the second most common cause of alopecia in childhood; no FDA-approved treatments exist. The use of focused narrow-band ultraviolet-B light via the excimer laser is a common treatment for many skin diseases in patients of all ages. In this study, the feasibility of the 308-nm excimer laser for treatment of patch type AA of the scalp will be examined. We anticipate the excimer laser will be safe and a feasible option for patients with patch type AA. The excimer laser may represent a novel treatment for childhood AA and no comparison or large studies currently exist in the literature. Hypotheses The 308-nm excimer laser procedure is a feasible, well-tolerated and safe treatment for patch type alopecia areata of the scalp in children.
Who is eligible to participate?
Inclusion Criteria: 1. Children 6-17 years old, diagnosed with patch type alopecia areata for a minimum of 6 months prior to enrollment involving the scalp. 2. A Parent/guardian consent and child assent (in those 8 years old or greater) must be obtained. 3. Parent/guardian and patient agree to MED dose test with a 24 hour follow up visit and a 12 week period of twice weekly treatment in either group, as well as baseline, interim and end of study visits. 4. Parent/guardian and child must be able to understand English or Spanish to participate. 5. Parent/guardian must agree to have the patient undergo a washout period of 6 weeks prior to the enrollment of the study if the patient is currently on treatment of any kind (oral and/or topical) for AA. Exclusion Criteria: 1. Children who have been diagnosed with an autoimmune skin disease or photosensitivity disorder. 2. Children who have been using topical steroids to the scalp, have other scalp disease or are using injected or oral steroids, biologic agents or chemotherapy for other medical conditions. 3. Children under current treatment for other skin conditions with oral medications (such as an oral corticosteroid) and/or topical treatments such as topical corticosteroids that may affect hair regrowth. Specifically, for topical medications, any child that requires the use of class 1-2 topical corticosteroids will be excluded. 3. Any subject who is currently experiencing significant spontaneous regrowth of terminal hair. 4. Patients with alopecia universalis, totalis, ophiasis pattern or diffuse AA may not participate in this feasibility study. 4. Parent/guardian who do not consent or children who do not assent to participate. 5. Any subject who has had AA for less than 6 months and is not willing to undergo a 6 week wash-out period prior to start of the study.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Device:308-nm excimer laser to alopecia patchMED dosing as per protocol with beginning at 50 mJ/cm2 below MED with increases by 50mJ/cm2 every 2 treatments as tolerated. Maximum dosing would be 850mJ.Treatments given twice a week for 12 weeks.
Device:Liquid light guide tip on laserSham treatment involves placement of liquid light guide tip developed by the laser company which attaches to the end of the hand wand and blocks the laser light from passing to the target. Patients are treated twice a week for 12 weeks.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Liquid light guide tip on laserExcimer laser treatment with 308-nm excimer laser with guide tip applied to alopecia patch twice a week.
308-nm excimer laser to alopecia patchLaser treatment with 308-nm excimer laser procedure to alopecia patch twice a week with increasing fluence as tolerated.
Start Date: August 2012
Completed Date: August 2014
Primary Outcome: The goal of this study is to assess the feasibility, safety and response to treatment of the use of the 308-nm excimer laser in children diagnosed with patch type alopecia areata involving the scalp, present for more than 6 months duration
Secondary Outcome: Evaluate the feasibility and safety of twice-weekly excimer laser treatments over a period of 12 weeks
Study sponsors, principal investigator, and references
Principal Investigator: Harper N Price, MD
Lead Sponsor: Phoenix Children's Hospital